Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Surmodics stock price, quote, forecast and news

SRDX
US8688731004
914178

Price

39.71
Today +/-
-0.22
Today %
-0.63 %
P

Surmodics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Surmodics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Surmodics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Surmodics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Surmodics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Surmodics Stock Price History

DateSurmodics Price
8/23/202439.71 undefined
8/22/202439.96 undefined
8/21/202440.06 undefined
8/20/202440.02 undefined
8/19/202440.12 undefined
8/16/202440.06 undefined
8/15/202439.72 undefined
8/14/202439.31 undefined
8/13/202440.02 undefined
8/12/202441.04 undefined
8/9/202441.10 undefined
8/8/202441.11 undefined
8/7/202441.05 undefined
8/6/202441.25 undefined
8/5/202441.00 undefined
8/2/202441.24 undefined
8/1/202441.31 undefined
7/31/202441.40 undefined
7/30/202441.50 undefined
7/29/202441.40 undefined
7/26/202441.44 undefined
7/25/202441.55 undefined

Surmodics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Surmodics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Surmodics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Surmodics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Surmodics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Surmodics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Surmodics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Surmodics’s growth potential.

Surmodics Revenue, EBIT and net profit per share

DateSurmodics RevenueSurmodics EBITSurmodics Net Income
2026e157.07 M undefined3.81 M undefined3.8 M undefined
2025e140.46 M undefined-3 M undefined-6.85 M undefined
2024e125.71 M undefined-8.3 M undefined-8.1 M undefined
2023132.58 M undefined6.43 M undefined-1.54 M undefined
2022100 M undefined-22.1 M undefined-27.3 M undefined
2021105.1 M undefined11.3 M undefined4.2 M undefined
202094.9 M undefined-1.3 M undefined1.1 M undefined
2019100.1 M undefined7.4 M undefined7.6 M undefined
201881.3 M undefined-900,000 undefined-4.5 M undefined
201773.1 M undefined7.1 M undefined3.9 M undefined
201671.4 M undefined20.1 M undefined10 M undefined
201561.9 M undefined21.6 M undefined11.9 M undefined
201457.4 M undefined18.6 M undefined12 M undefined
201356.1 M undefined19.3 M undefined15.2 M undefined
201251.9 M undefined16.3 M undefined10.2 M undefined
201152.8 M undefined17.1 M undefined-18.5 M undefined
201054.5 M undefined16.2 M undefined-21.1 M undefined
2009121.5 M undefined62.5 M undefined37.6 M undefined
200897.1 M undefined27.3 M undefined14.7 M undefined
200773.2 M undefined25.5 M undefined3.3 M undefined
200669.9 M undefined36.2 M undefined20.3 M undefined
200562.4 M undefined35.8 M undefined-8.2 M undefined
200449.7 M undefined27 M undefined7.2 M undefined

Surmodics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
4466791318222943496269739712154525156576171738110094105100132125140157
--50.00-16.6728.5744.4438.4622.2231.8248.2813.9526.5311.295.8032.8824.74-55.37-3.70-1.929.801.797.0216.392.8210.9623.46-6.0011.70-4.7632.00-5.3012.0012.14
25.0025.0016.6716.6728.5744.4446.1550.0054.5558.6265.1269.3969.3566.6753.4271.1382.6487.0488.4686.2785.7185.9686.8984.5183.5682.7286.0084.0483.8179.0081.06---
11112469121728344346396910047464448495360616786798879107000
0-10000257102027353625276216171619182120707-111-226-8-33
--25.00----15.3827.7831.8234.4846.5155.1056.4552.1734.2527.8451.2429.6332.6931.3733.9331.5834.4328.179.59-7.00-1.0610.48-22.004.55-6.40-2.141.91
0-100014457137-82031437-21-1810151211103-4714-27-1-8-63
------300.00-25.0040.0085.71-46.15-214.29-350.00-85.00366.67164.29-156.76-14.29-155.5650.00-20.00-8.33-9.09-70.00-233.33-275.00-85.71300.00-775.00-96.30700.00-25.00-150.00
8.18.69.69.610.813.616.116.817.917.817.817.818.118.718.218.317.517.417.517.414.713.913.313.213.413.213.813.81413.914.03000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Surmodics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Surmodics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
3.81.94.95.917.414.813.16.619.224.458.826.324.620.620.538.429.725.746.655.646.948.364.755.361.138.91945.35
0.60.91.11.41.43.25.59.18.11114.516.114.611.394.45.15.34.87.56.97.28.917.213.816.317.618.65
0000000003.600000000000.70.61.10.62.41.92.41.81
0.30.30.40.50.50.70.70.911.112.52.73.333.23.53.32.833.63.544.566.811.814.84
0.10.10.30.31.81.21.51.11.21.51.82.94.71.84.98.61.71.51.21.70.51.22.93.93.46.56.86.04
4.83.26.78.121.119.920.817.729.541.676.147.846.63737.454.64035.855.467.858.660.881.681.586.770.457.686.69
1.21.11.25.37.27.718.833.915.714.811.719.741.966.965.414.613.612.813.11319.622.930.129.732.632.530.829.01
01.916.215.922.329.630.739.244.148.947.843.947.438.440.93328.432.416.8000000200
0000000000000000000000000000
000000.20.20.27.45.95.518.416.917.515.35.24.43.72.92.822.520.617.714.213.337.128.126.21
0000000000015.71821.188888826.627.32726.227.245.640.742.95
00.30.32.70.23.16.66.812.81316.325.720.44.73.241.49.99.28.77.25.74.97.88.39.17.21.10.88
1.23.317.723.929.740.656.380.18082.681.3123.4144.6148.6132.8102.264.366.149.53174.475.782.678.482.2124.4100.799.04
66.524.43250.860.577.197.8109.5124.2157.4171.2191.2185.6170.2156.8104.3101.9104.998.8133136.5164.2159.9168.9194.8158.3185.73
200200400800800800900900900900900900900900900900700700700600700700700700700700700708
13.113.328.831.645.747.853.956.557.889.796.376.774.66669.774.518.322.73.16.85.47.610.715.421.628.836.71
-8.4-8.2-6.5-2.22.17.21528.936.227.948.351.666.410482.964.475.99193.988.298.1102.197.6110.7111.8116.188.887.26
-0.1-0.30.1-0.5-0.3-0.10.2-0.1-0.6-3-0.31.7-0.11.50.9-0.200.11.501.33.42.70.43.21.7-9.9-4.76
0000000000000000000000000000
4.8522.829.748.355.77086.294.3115.5145.2130.9141.8172.4154.4139.694.993.898.891.9106.9111.6108.6122.5131.1140.1108.4119.91
0.10.30.30.70.40.60.91.10.71.212.53.53.53.31.61.7110.82.52.42.52.11.51.83.12.99
0.30.511.31.61.33.96.36.83.52.94.24.42.62.73.23.44.42.93.96.55.611.99.412.213.414.816.58
0.50.30.20.30.40.70.32.64.40.45.113.14.621.66.31.90.60.101.11.820.78.85.24.64.24.38
000000000000000000000000010100
0000000000000000000000000000
0.91.11.52.32.42.65.11011.95.1919.812.58.17.611.17644.710.19.835.120.318.929.832.123.95
00000000000000000000000000029.41
00000000000000000000000002.722
0.50.30.100.12.42.21.63.53.53.220.636.75.28.36.12.42.12.12.115.915.220.417.118.82215.910.46
0.50.30.100.12.42.21.63.53.53.220.636.75.28.36.12.42.12.12.115.915.220.417.118.824.717.941.87
1.41.41.62.32.557.311.615.48.612.240.449.213.315.917.29.48.16.16.8262555.537.437.754.55065.82
6.26.424.43250.860.777.397.8109.7124.1157.4171.3191185.7170.3156.8104.3101.9104.998.7132.9136.6164.1159.9168.8194.6158.4185.73
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Surmodics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Surmodics's financial health and stability.

Assets

Surmodics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Surmodics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Surmodics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Surmodics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00014457137-82031437-21-181015121193-4714-27-1
00000111233346533222245677898
0000-21000-55-2-9-38-2-1000001-2-1-1150
000000-10-11-94288-3256200-24021-91-4-12-4
00001024017358242319423343659717911121415
00000000000000000000000000002
0000001147131114211140276662000002
0002477141723253550393122191617181525143481415-1710
0000-4-2-2-13-15-5-7-7-4-26-30-2-10-1-2-1-8-6-14-6-3-6-3-2
-10-2-16-5-210-15-23-25-27-38-10-26-19-27-135902216-55-16-239-9-256-6
-11-1-160-181-2-7-19-20-31-5010-24-116022418-47-9-916-5-189-3
00000000000000000000000000000
-1000000000000000000000000010019
00015113011023-30-10-14-10-54-17-12-190-4201311
-10015113011023-29-11-1555-83-17-12-190-6-3-11-410018
00000000000000064-280000-2-5-11-6-2-1-2
00000000000000000000000000000
-21-100070-5-110101-3011-702812-30-87600-1222
-0.110.170.231.34-0.314.395.761.311.5917.6518.627.8345.7413.51.3219.0218.4115.3515.7515.913.1416.987.6219.961.2910.349.11-20.597.6
00000000000000000000000000000

Surmodics stock margins

The Surmodics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Surmodics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Surmodics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Surmodics's sales revenue. A higher gross margin percentage indicates that the Surmodics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Surmodics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Surmodics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Surmodics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Surmodics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Surmodics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Surmodics Margin History

Surmodics Gross marginSurmodics Profit marginSurmodics EBIT marginSurmodics Profit margin
2026e81.17 %2.43 %2.42 %
2025e81.17 %-2.14 %-4.88 %
2024e81.17 %-6.61 %-6.44 %
202381.17 %4.85 %-1.16 %
202279.6 %-22.1 %-27.3 %
202184.21 %10.75 %4 %
202083.77 %-1.37 %1.16 %
201986.31 %7.39 %7.59 %
201882.78 %-1.11 %-5.54 %
201784.4 %9.71 %5.34 %
201684.73 %28.15 %14.01 %
201586.11 %34.89 %19.22 %
201486.06 %32.4 %20.91 %
201385.92 %34.4 %27.09 %
201285.74 %31.41 %19.65 %
201187.12 %32.39 %-35.04 %
201087.52 %29.72 %-38.72 %
200982.96 %51.44 %30.95 %
200871.47 %28.12 %15.14 %
200753.42 %34.84 %4.51 %
200665.95 %51.79 %29.04 %
200569.71 %57.37 %-13.14 %
200468.61 %54.33 %14.49 %

Surmodics Stock Sales Revenue, EBIT, Earnings per Share

The Surmodics earnings per share therefore indicates how much revenue Surmodics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Surmodics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Surmodics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Surmodics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Surmodics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Surmodics Revenue, EBIT and net profit per share

DateSurmodics Sales per ShareSurmodics EBIT per shareSurmodics Earnings per Share
2026e11.01 undefined0 undefined0.27 undefined
2025e9.85 undefined0 undefined-0.48 undefined
2024e8.82 undefined0 undefined-0.57 undefined
20239.45 undefined0.46 undefined-0.11 undefined
20227.19 undefined-1.59 undefined-1.96 undefined
20217.51 undefined0.81 undefined0.3 undefined
20206.88 undefined-0.09 undefined0.08 undefined
20197.25 undefined0.54 undefined0.55 undefined
20186.16 undefined-0.07 undefined-0.34 undefined
20175.46 undefined0.53 undefined0.29 undefined
20165.41 undefined1.52 undefined0.76 undefined
20154.65 undefined1.62 undefined0.89 undefined
20144.13 undefined1.34 undefined0.86 undefined
20133.82 undefined1.31 undefined1.03 undefined
20122.98 undefined0.94 undefined0.59 undefined
20113.02 undefined0.98 undefined-1.06 undefined
20103.13 undefined0.93 undefined-1.21 undefined
20096.94 undefined3.57 undefined2.15 undefined
20085.31 undefined1.49 undefined0.8 undefined
20074.02 undefined1.4 undefined0.18 undefined
20063.74 undefined1.94 undefined1.09 undefined
20053.45 undefined1.98 undefined-0.45 undefined
20042.79 undefined1.52 undefined0.4 undefined

Surmodics business model

Surmodics Inc is an American company specializing in medical technology, based in Eden Prairie, Minnesota. They focus on developing and commercializing technologies to improve disease diagnosis and treatment. The company offers a wide range of medical devices and solutions for various medical applications, including cardiology, radiology, oncology, ophthalmology, and pharmaceutical development. Surmodics operates in three main business areas: medical devices, hollow fiber technology, and bioactive coatings. Their products are designed to meet the specific needs of customers and medical applications. Surmodics has a strong global presence and has expanded through strategic acquisitions in recent years, particularly in the pharmaceutical development and hollow fiber technology sectors. Surmodics is one of the most popular companies on Eulerpool.com.

Surmodics SWOT Analysis

Strengths

  • Established brand with a good reputation in the healthcare industry.
  • Diverse portfolio of innovative medical devices and diagnostic products.
  • Strong intellectual property rights, providing a competitive advantage.
  • Solid financial position and consistent revenue growth.

Weaknesses

  • Reliance on a limited number of major customers, posing a potential risk.
  • Vulnerability to changes in government regulations and reimbursement policies.
  • Limited global presence compared to some competitors.
  • Potential product recalls or legal issues may impact reputation and financials.

Opportunities

  • Growing demand for minimally invasive medical procedures, offering market expansion prospects.
  • Increasing focus on personalized medicine and companion diagnostics.
  • Potential partnerships and collaborations to enhance product offerings and market reach.
  • Continuous advancements in medical technology present opportunities for product innovation.

Threats

  • Intense competition from larger and more established companies.
  • Economic downturns affecting healthcare spending and customer budget constraints.
  • Rapidly evolving regulatory landscape impacting product development and market access.
  • Potential disruptions in supply chain and manufacturing processes.

Surmodics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Surmodics historical P/E ratio, EBIT, and P/S ratio.

Surmodics shares outstanding

The number of shares was Surmodics in 2023 — This indicates how many shares 14.031 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Surmodics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Surmodics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Surmodics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Surmodics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Surmodics Stock splits

In Surmodics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Surmodics.

Surmodics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.34 -0.27  (19.79 %)2024 Q3
3/31/2024-0.33 0.07  (121.45 %)2024 Q2
12/31/2023-0.31 0  (100 %)2024 Q1
9/30/20230.19 0.53  (180.87 %)2023 Q4
6/30/20230.05 0.52  (873.78 %)2023 Q3
3/31/2023-0.52 -0.4  (22.85 %)2023 Q2
12/31/2022-0.67 -0.5  (25.27 %)2023 Q1
9/30/2022-0.46 -0.26  (43.53 %)2022 Q4
6/30/2022-0.39 -0.34  (13.04 %)2022 Q3
3/31/2022-0.35 -0.22  (36.56 %)2022 Q2
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Surmodics stock

Eulerpool World ESG Rating (EESG©)

64/ 100

🌱 Environment

73

👫 Social

49

🏛️ Governance

71

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Surmodics list of shareholders

%
Name
Stocks
Change
Date
8.08 % Morgan Stanley & Co. LLC1,152,4911,128,55212/31/2023
7.03 % BlackRock Institutional Trust Company, N.A.1,002,51057,36712/31/2023
6.03 % The Vanguard Group, Inc.859,28713,12312/31/2023
5.41 % Soleus Capital Management, L.P.771,700-459,16212/31/2023
4.71 % Millennium Management LLC671,551-36,04812/31/2023
4.31 % Disciplined Growth Investors, Inc.614,89119,18812/31/2023
4.10 % Renaissance Technologies LLC584,1386,07312/31/2023
2.95 % Royce Investment Partners420,412131,80712/31/2023
2.83 % Segall Bryant & Hamill, LLC404,1701,41512/31/2023
2.64 % Dimensional Fund Advisors, L.P.375,899-1,26812/31/2023
1
2
3
4
5
...
10

Surmodics Executives and Management Board

Mr. Gary Maharaj60
Surmodics President, Chief Executive Officer, Director (since 2010)
Compensation 3.53 M
Ms. Teri Sides54
Surmodics Senior Vice President, President - Vascular Interventions
Compensation 1.49 M
Mr. Timothy Arens56
Surmodics Chief Financial Officer, Senior Vice President - Finance and Information Technology
Compensation 1.3 M
Mr. Charles Olson59
Surmodics Senior Vice President, President - Medical Device Coatings
Compensation 1.12 M
Mr. Gordon Weber60
Surmodics Senior Vice President - Legal, General Counsel, Secretary
Compensation 1.1 M
1
2
3

Surmodics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Boston Scientific Stock
Boston Scientific
SupplierCustomer0,880,850,900,500,500,50
Abbott Laboratories Stock
Abbott Laboratories
SupplierCustomer0,860,910,920,840,190,41
Medtronic Stock
Medtronic
SupplierCustomer0,830,860,830,260,900,78
Cardinal Health Stock
Cardinal Health
SupplierCustomer0,670,640,19-0,40-0,270,21
Cosmo Bio Stock
Cosmo Bio
SupplierCustomer0,47-0,17-0,250,590,740,37
Koninklijke Philips Stock
Koninklijke Philips
SupplierCustomer0,220,330,880,890,950,40
Qualigen Therapeutics Stock
Qualigen Therapeutics
SupplierCustomer0,100,770,720,750,77-0,21
Edwards Lifesciences Stock
Edwards Lifesciences
SupplierCustomer-0,69-0,15-0,270,18-0,160,16
1

Most common questions regarding Surmodics

What values and corporate philosophy does Surmodics represent?

Surmodics Inc is a leading provider of medical device and in vitro diagnostic technologies. The company operates with a strong set of values and corporate philosophy that underpins its actions and decisions. Surmodics is committed to innovation, continuously striving to develop breakthrough solutions that positively impact patient outcomes. The company places a strong emphasis on integrity, conducting business with the highest ethical standards and fostering a culture of accountability. Surmodics also embraces collaboration, working closely with customers, partners, and internal teams to deliver the most advanced solutions. With a focus on quality, Surmodics ensures that its products meet the highest standards of reliability and performance, putting patient safety and well-being at the forefront of its operations. Overall, Surmodics Inc represents a commitment to innovation, integrity, collaboration, and quality in the medical device industry.

In which countries and regions is Surmodics primarily present?

Surmodics Inc is primarily present in the United States.

What significant milestones has the company Surmodics achieved?

Surmodics Inc has achieved significant milestones in its history. The company introduced its first medical device coating product, SurfaSeal, in 1985, which marked a breakthrough in the field. In 1998, Surmodics launched its first drug delivery coating called BioFX. The company developed StabilCoat Plus, a surface modification technology used in cardiovascular devices in 2003. In 2019, Surmodics received FDA approval for its SurVeil™ drug-coated balloon, offering a breakthrough treatment option for peripheral artery disease patients. With continuous innovation and dedication, Surmodics Inc strives to make impactful advancements in the medical technology industry.

What is the history and background of the company Surmodics?

Surmodics Inc, founded in 1979, is a leading provider of surface modification and in vitro diagnostic technologies. With its headquarters in Eden Prairie, Minnesota, the company develops and manufactures innovative products that enhance the performance of medical devices, improve drug delivery, and support the diagnosis of various diseases. Surmodics has a rich history of pioneering advancements in healthcare, and its expertise in surface modification has helped it establish collaborations with renowned medical device manufacturers globally. As a trusted name in the industry, Surmodics Inc continues to drive innovation and deliver solutions that positively impact patient outcomes and empower healthcare professionals worldwide.

Who are the main competitors of Surmodics in the market?

The main competitors of Surmodics Inc in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.

In which industries is Surmodics primarily active?

Surmodics Inc is primarily active in the healthcare and medical device industry.

What is the business model of Surmodics?

Surmodics Inc. is a medical technology company that operates through two segments: Medical Devices and In Vitro Diagnostics. The company's business model revolves around developing and commercializing innovative products and technologies that enhance the diagnosis and treatment of diseases. Surmodics' Medical Devices segment focuses on providing surface modification technologies to medical device manufacturers, enabling them to improve device performance and biocompatibility. On the other hand, the In Vitro Diagnostics segment offers proprietary diagnostic technologies and reagent coatings for various healthcare tests. Through its diversified business model, Surmodics strives to contribute to the advancement of medical care and improve patient outcomes.

What is the P/E ratio of Surmodics 2024?

The Surmodics P/E ratio is -68.81.

What is the P/S ratio of Surmodics 2024?

The Surmodics P/S ratio is 4.43.

What is the AlleAktien quality score of Surmodics?

The AlleAktien quality score for Surmodics is 3/10.

What is the revenue of Surmodics 2024?

The expected Surmodics revenue is 125.71 M USD.

How high is the profit of Surmodics 2024?

The expected Surmodics profit is -8.1 M USD.

What is the business model of Surmodics

Surmodics Inc. is a renowned manufacturer of medical devices and products used in in vitro diagnostics, medical technology, and drug delivery. The company offers a wide range of innovative solutions based on nanotechnology and surface chemistry. Its core competencies include the development and manufacturing of medical coatings that can be applied to polymers, metals, and glass. These coatings are capable of improving the performance and extending the lifespan of medical devices and products. Surmodics Inc. also specializes in the development and manufacturing of reagents and detection devices for in vitro diagnostics, offering specialized kits and assays for quick and reliable determination of clinical parameters such as blood sugar levels or inflammation indicators. In the field of medical technology, Surmodics Inc. is mainly focused on the development of minimally invasive catheters and implants. These products are equipped with special coatings that prevent the penetration of bacteria and other pathogens, thus minimizing the risk of infections. Surmodics Inc. is also a key player in the drug delivery market, offering a wide range of products based on micro and nanotechnology. These include implants that release precisely dosed active ingredients, as well as intelligent delivery systems that automatically adapt to the individual needs of the patient. Surmodics Inc. is a strong and highly innovative company known for its continuous product development and quality assurance. The company works closely with its customers to develop individual solutions that meet their specific requirements.

What is the Surmodics dividend?

Surmodics pays a dividend of 0 USD distributed over payouts per year.

How often does Surmodics pay dividends?

The dividend cannot currently be calculated for Surmodics or the company does not pay out a dividend.

What is the Surmodics ISIN?

The ISIN of Surmodics is US8688731004.

What is the Surmodics WKN?

The WKN of Surmodics is 914178.

What is the Surmodics ticker?

The ticker of Surmodics is SRDX.

How much dividend does Surmodics pay?

Over the past 12 months, Surmodics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Surmodics is expected to pay a dividend of 0 USD.

What is the dividend yield of Surmodics?

The current dividend yield of Surmodics is .

When does Surmodics pay dividends?

Surmodics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Surmodics?

Surmodics paid dividends every year for the past 0 years.

What is the dividend of Surmodics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Surmodics located?

Surmodics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Surmodics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Surmodics from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Surmodics pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Surmodics in the year 2023?

In the year 2023, Surmodics distributed 0 USD as dividends.

In which currency does Surmodics pay out the dividend?

The dividends of Surmodics are distributed in USD.

All fundamentals about Surmodics

Our stock analysis for Surmodics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surmodics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.